Formulary Search Results for: CALCIUM AND VITAMIN D
13.5.3 Drugs affecting the immune response - View Category
Restrictions:
Restricted to specialist use in accordance with local guidelines in patients with the following indications:
Psoriasis
Patients with moderate to severe psoriasis who have failed to respond to standard systemic therapies, are intolerant to, or have a contra-indication to these treatments.
Hidradenitis suppurativa (HS)
Adult patients with active moderate to severe HS for whom adalimumab is contraindicated or otherwise unsuitable, including those who have failed to respond or have lost response to prior adalimumab treatment.
9.1.8 Drugs for other blood disorders - View Category
Restrictions:
Restricted to use under the advice of the national paroxysmal nocturnal haemoglobinuria (PNH) service as add-on to ravulizumab or eculizumab for the treatment of adult patients with PNH who have residual haemolytic anaemia.
13.5.3 Drugs affecting the immune response - View Category
Restrictions:
Restricted to specialist use in the treatment of:
- Moderate to severe plaque psoriasis in accordance with local guidelines in patients who have failed to respond to conventional systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have contra-indications to these treatments.
- Moderate to severely active Crohn's disease in patients 16 year of age and older, who have an inadequate response to, lost response to, or where intolerant to conventional therapy, or if such therapies are not advisable.
13.5.3 Drugs affecting the immune response - View Category
Restrictions:
Restricted to specialist use in accordance with the prescribing notes below.
Prescribing Notes:
Psoriasis in adults:
- The treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systematic therapies including ciclosporin, methotrexate and psoralen and UVA treatment (PUVA) is restricted to specialist use. Continued treatment should be restricted to patients who achieve a PASI 75% response within 16 weeks.
Psoriasis in adolescents:
- The treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies is restricted to specialist use. Continued treatment should be restricted to patients who achieve at least 75% improvement in their Psoriasis Area and Severity Index (PASI 75) within 16 weeks.
For use in psoriatic arthritis see section 10.1.3 and for use in Crohn's disease see section 1.5.3
13.5.3 Drugs affecting the immune response - View Category
Restrictions:
Restricted to specialist use for moderate to severe atopic dermatitis in patients who have had an
inadequate response to at least one conventional systemic immunosuppressant such as ciclosporin, or
in whom such treatment is considered unsuitable.
Prescribing Notes:
Following a MHRA review in April 2023, the risk of increased incidence of malignancy, major adverse cardiovascular events (MACE), serious infections, venous thromboembolism (VTE) and mortality, when compared to those treated with tumour necrosis factor (TNF)-alpha inhibitors, were are considered a class effects across JAK inhibitors used for chronic inflammatory disorders and therefore it is advised to avoid prescribing these medicines unless there are no suitable alternatives in patients with the following risk factors:
- age 65 years or older
- current or past long-time smoking
- other risk factors for cardiovascular disease or malignancy
Please see further details of the review here.
12.1.1 Otitis externa - View Category
9.6.2 Vitamin B group - View Category
5.1.7 Some other antibacterials - View Category
Restrictions:
Restricted to use on the advice of local microbiologists and infectious disease specialists only in the following situations:
- in accordance with OPAT service clinical management pathway for second-line use or when meticillin-resistant Staphylococcus aureus (MRSA) infection is suspected AND when the patient is initially hospitalised due to ABSSSI, requires intravenous antibiotics, but is eligible for early discharge as soon as their medical condition does not require further inpatient treatment.
Prescribing Notes:
Please note: this is a PROTECTED ANTIBIOTIC (see policy here) and relevant paper work should be completed.
5.1.7 Some other antibacterials - View Category
Restrictions:
Restricted to specialist initiation by a microbiologist or specialist in infectious diseases. Restricted to use in patients not responding to or intolerant of a glycopeptide, or those with microbiological cultures which indicate glycopeptide resistance.
Prescribing Notes:
Please note, this is a PROTECTED ANTIBIOTIC (see policy here) and relevant paper work should be completed.
For daptomycin dosing in adults click here
5.1.7 Some other antibacterials - View Category
Restrictions:
Fidaxomicin is restricted to use for the treatment of adults with microbiologically proven recurrence of Clostridium difficile infection (CDI) only on the advice of Consultant microbiologists or Consultants in Infectious Diseases.
Please note: this is a PROTECTED ANTIBIOTIC (see policy here) and relevant paper work should be completed.
It is non-formulary for use in adults with first episode of CDI or as empirical treatment in CDI.